Form 4: HeartBeam Director Granted 51,724 Stock Options

HeartBeam, Inc. Director George de Urioste was granted 51,724 stock options with an exercise price of $1.43, vesting in two tranches by June 2026.

Summary

• George de Urioste, a Director of HeartBeam, Inc. (BEAT), was granted 51,724 stock options.
• The options have an exercise price of $1.43 per share.
• The vesting commencement date for these options was January 1, 2026.
• One half of the total options (25,862 shares) will vest on March 31, 2026, which is the three-month anniversary of the vesting commencement date.
• The remaining half of the options (25,862 shares) will vest on June 30, 2026, the six-month anniversary of the vesting commencement date.
• These options were issued from the Company's 2022 Equity Incentive Plan.
• The options have an expiration date of January 1, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine compensation event, slightly positive as it aligns a director's interests with long-term shareholder value through equity ownership, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and shareholder value.
• The options are issued from an established 2022 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

The options are scheduled to vest in two tranches, with the first half vesting on March 31, 2026, and the remaining half on June 30, 2026, indicating a future alignment of the director's interests with the company's performance over this period.

Industry Context

StockSavvy.ai notes that option grants are a common form of executive and director compensation across various industries, including healthcare technology. This practice is designed to align the interests of key personnel with the long-term performance and shareholder value of the company, incentivizing them to contribute to sustained growth.

Comparison to Industry Standards

• StockSavvy.ai observes that granting options from an approved equity incentive plan is a standard practice for public companies like HeartBeam, Inc. in the medical device or healthcare technology sector.
• This compensation method is comparable to practices at peer companies such as iRhythm Technologies (IRTC) or AliveCor, where equity compensation is utilized to attract and retain talent and align management interests with shareholder returns.
• The specific number of options and vesting schedule would typically be benchmarked against peer companies based on factors like company size, performance, and the individual's role and responsibilities.

Corporate Governance

Related Party Transactions

• The grant of stock options to George de Urioste, a Director of HeartBeam, Inc., constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: While this specific filing is for a director, the use of an equity incentive plan can signal a broader strategy for employee retention and motivation through equity.

Next Steps

• The first half of the granted options are scheduled to vest on March 31, 2026.
• The remaining half of the granted options are scheduled to vest on June 30, 2026.

Key Dates

Keywords

HeartBeam, BEAT, stock options, insider transaction, Form 4, George de Urioste, equity incentive plan, director compensation